Results 231 to 240 of about 559,012 (379)

The clinical spectrum of SMA‐PME and in vitro normalization of its cellular ceramide profile

Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1941-1952, December 2022., 2022
Abstract Objective The objectives of this study were to define the clinical and biochemical spectrum of spinal muscular atrophy with progressive myoclonic epilepsy (SMA‐PME) and to determine if aberrant cellular ceramide accumulation could be normalized by enzyme replacement.
Michelle M. Lee, Graeme S. V. McDowell, Darryl C. De Vivo, Daniel Friedman, Samuel F. Berkovic, Maria Spanou, Argirios Dinopoulos, Katheryn Grand, Pedro A. Sanchez‐Lara, Michelle Allen‐Sharpley, Jodi Warman‐Chardon, Alexander Solyom, Thierry Levade, Edward H. Schuchman, Steffany A. L. Bennett, David A. Dyment, Toni S. Pearson   +16 more
wiley   +1 more source

Intracellular and intramitochondrial sorting of precursor proteins [PDF]

, 1987
Neupert, Walter, Ozawa, Takayuki, Papa, S., Schwaiger, Martin   +3 more
core   +1 more source

Nonparticipation of 105,000 x g liver supernatant or sterol carrier protein in the enzymatic conversion of farnesyl pyrophosphate to squalene by rat liver microsomes

, 1978
K.L. Gavey, Terence J. Scallen
openalex   +1 more source

The impact of solute carrier proteins on disrupting substance regulation in metabolic disorders: insights and clinical applications. [PDF]

Front Pharmacol
Du J, Shen M, Chen J, Yan H, Xu Z, Yang X, Yang B, Luo P, Ding K, Hu Y, He Q.   +10 more
europepmc   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

A transient inflammatory response contributes to oxaliplatin neurotoxicity in mice

Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1985-1998, December 2022., 2022
Abstract Objectives Peripheral neuropathy is a relevant dose‐limiting adverse event that can affect up to 90% of oncologic patients with colorectal cancer receiving oxaliplatin treatment. The severity of neurotoxicity often leads to dose reduction or even premature cessation of chemotherapy.
Aina Calls, Abel Torres‐Espin, Marc Tormo, Laura Martínez‐Escardó, Núria Bonet, Ferran Casals, Xavier Navarro, Víctor J. Yuste, Esther Udina, Jordi Bruna   +9 more
wiley   +1 more source

Rat adrenal corticosteroidogenesis; Effect of ACTH, cycloheximide and sterol carrier protein.

, 1977
SHOGO ICHII, Noriko Murakami, Ryuichi Sakata   +2 more
openalex   +2 more sources

Elucidating the role of carrier proteins in cytokine stabilization within double emulsion-based polymeric nanoparticles. [PDF]

Bioeng Transl Med
Rhodes ER, Day NB, Aldrich EC, Wyatt Shields C, Sprenger KG.   +4 more
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Synthesis and intracellular transport of mitochondrial proteins [PDF]

, 1985
A Lustig, A Lustig, A Ohashi, A Viebrock, AJ Lamb, AP Autor, AS Lewin, AS Lewin, B Hennig, B Schmidt, BE Roberts, BG Barrell, C Cote, C Zwizinski, CJ Leaver, DI Meyer, DI Meyer, DL Stigall, DM Kolansky, E Komar, E Marra, E Pratje, E Schmelzer, G Attardi, G Blobel, G Daum, G Daum, G Hallermayer, G Hallermayer, G Kreibich, G Kreil, G Macino, G Reid, G Schatz, G Schatz, G Schatz, G Srivastava, GC Shore, GC Shore, H Freitag, H Koehler, H Korb, H Riezman, H Weiss, IG Macreadie, IZ Ades, IZ Ades, J Kaput, JG Conboy, JP Kraus, K Mihara, K Mihara, K Mihara, K Watanabe, L Ernster, L Randall, LA Grivell, LE Aziz, M Inouye, M Klingenberg, M Klingenberg, M Maccechini, M Mori, M Mori, M Schleyer, M Suissa, M Teintze, M Wikstrom, M Yamamoto, M-L Maccechini, MA Harmey, MA Harmey, MD Hampsey, MM Mueckler, N Cerletti, N Nabi, N Nelson, NK Bhat, P Boehni, P Boehni, P Boogart van den, P Borst, P Borst, P Borst, P McAda, P Sonderegger, P Walter, PC Heinrich, PC Kreibich, PG Adolphus, R Jaussi, R Michel, R Sakakibara, R Zimmermann, R Zimmermann, R Zimmermann, R Zimmermann, RE Kellems, RE Kellems, RO Poyton, S Matsuura, S Miura, S Passarella, S Werner, SD Emr, SM Gasser, SM Gasser, SM Gasser, T Hunt, T Monta, T Oda, VA Rucker, W Neupert, W Wickner, Y Kamisaki, Y Raymond, Y Sagara, Y Yoshida   +117 more
core   +1 more source